What a Medical Manager Does in Global Drug Development

A medical manager in global drug development helps translate clinical science into documented program and study decisions. The title itself is not standardized by ICH guidance or by one universal law. Depending on the organization, the function may support evidence strategy, protocol design, medical monitoring, benefit-risk assessment, safety governance, document review, or regional coordination. The reliable description is therefore a map of assigned work, not a claim that every person with the title has the same authority.

This is a neutral role explainer. It does not describe any named person, employer, product, or professional history. Exact qualifications, reporting lines, delegated duties, and signatory authority vary and must be defined in the sponsor's operating model.

Key takeaways#

• ICH standards define sponsor, investigator, safety, quality, and reporting responsibilities, but they do not create one universal “medical manager” role.
• Medical input helps keep the disease question, intended population, comparator, endpoints, procedures, and interpretation clinically coherent.
• Trial safety requires continuous review through defined processes, with clear escalation and decision rights rather than informal ownership.
• Global development adds regional populations, standards of care, operational conditions, and regulatory expectations that must be planned rather than explained after the fact.
• Strong performance is visible in decision quality, traceability, proportionality, and alignment, not simply the number of meetings or documents reviewed.

Start with responsibilities, not the title#

ICH E6(R3) places responsibility for initiating, managing, and financing a clinical trial with the sponsor and requires roles and activities to be allocated before work begins.[1] The sponsor should use appropriately qualified people and have medical personnel available to advise on specific trial-related medical questions. Those principles create a need for medical expertise. They do not prescribe the business title attached to it.

One organization may use “medical manager” for a study physician who handles day-to-day clinical questions. Another may use it for a program role that connects several studies, and a third may reserve the title for a regional function while assigning global strategy to a separate clinical lead. Medical monitor, clinical scientist, safety physician, medical director, and medical manager can overlap or remain distinct.

If you are writing or reading one of these role descriptions, a sound one names:

• The decisions the person prepares, recommends, approves, or only informs.
• The studies, regions, and documents in scope.
• The medical questions that require escalation.
• The interfaces with statistics, safety, operations, regulatory, quality, data management, and investigators.
• The governance bodies that hold final authority.
• The records that document advice and decisions.
• The coverage plan when the assigned person is unavailable.

Without those details, a title can create gaps or duplicate work, and you usually find out which only after something has gone wrong; two people may assume the other owns a safety question, or several teams may issue inconsistent clinical interpretations.

Translate a development objective into a clinical question#

Drug development begins with a decision the program needs to support. Is the question about dose, comparative benefit, long-term safety, a particular population, or a new use? The medical function helps express that objective in clinical terms before it becomes a protocol.

The core frame includes population, intervention, comparator, outcomes, time horizon, and the decision that follows. It also identifies the disease course, current care, unmet need, likely treatment pathway, and plausible benefit-risk tradeoff; an endpoint can be statistically measurable yet clinically weak if it does not matter to patients or does not fit how the disease changes.

Medical input tests whether the proposed question is coherent:

• Does the intended population match the likely use?
• Does the comparator reflect relevant care in each region?
• Is the treatment effect expected within the planned follow-up?
• Are benefits and harms measured on compatible time horizons?
• Will eligibility criteria exclude people central to the eventual decision?
• Can the result be interpreted if participants discontinue or use rescue therapy?

ICH E8(R1) emphasizes clear objectives, relevant populations, well-defined endpoints, operational feasibility, and early identification of factors critical to study quality.[2] A medical manager may facilitate that work, while statistics, clinical pharmacology, patient representatives, regulatory specialists, and other experts contribute their own disciplines.

Shape a protocol without pretending one function writes it alone#

A protocol is a cross-functional product. Medical responsibilities may include drafting or reviewing disease background, objectives, eligibility, interventions, prohibited or permitted therapies, safety assessments, withdrawal criteria, clinical endpoints, rescue rules, and the rationale for key choices.

The medical review should ask whether every procedure earns its burden. Collecting more data can feel safer to you but may distract sites, increase missingness, or deter participation. ICH E6(R3) and E8(R1) support risk-proportionate design and avoidance of unnecessary complexity.[1][2] Critical information deserves focus; merely interesting information may not.

Eligibility criteria illustrate the tradeoff. Very narrow criteria can create a homogeneous sample and a clean efficacy estimate while limiting relevance. Broad criteria can improve representativeness but introduce heterogeneity or safety needs. The medical function helps state why each exclusion exists and what future evidence gap it creates.

Endpoints require equal care. A biomarker may respond quickly, while function, symptoms, or complications take longer. A composite can increase event counts but combine outcomes of unequal importance. A patient-reported measure needs a clear concept, validated instrument, schedule, language plan, and strategy for missing data. Medical coherence means the outcome answers the stated question, not merely that a validated scale was available.

Connect evidence across studies without turning it into one story too early#

A development program accumulates evidence from laboratory work, pharmacology, early human studies, dose-finding, confirmatory trials, safety reports, and sometimes real-world sources. Medical management can maintain the logic that connects those pieces.

That includes a live record of assumptions. Why was a dose selected? Which population is expected to benefit? Which adverse events are biologically plausible? What uncertainty justifies another study? When new data conflict with an assumption, the discrepancy should be visible rather than edited out of the narrative.

Evidence strength must stay differentiated. A laboratory mechanism can support plausibility. A small uncontrolled study can support feasibility. A randomized comparison can estimate an assigned-treatment effect under its design. An exploratory subgroup can raise a question. None should be promoted silently to a stronger category.

The function may prepare an evidence summary for governance, but the summary should show both supportive and limiting findings. Useful decision material lets you tell apart:

• Verified facts from interpretation.
• Prespecified results from post hoc findings.
• Individual cases from aggregate patterns.
• Statistical uncertainty from other sources of uncertainty.
• Known risks from potential risks and missing information.
• Program evidence from assumptions imported from another product or population.

The companion article on what a clinical study report contains shows how one study's chain is documented. Program interpretation must then reconcile several such chains without hiding disagreement.

Support continuous safety review through defined governance#

Safety interpretation begins before the first participant and continues throughout development. Background disease events, nonclinical findings, class effects, prior studies, concomitant therapies, and emerging cases all contribute context.

A medical manager may review clinical details, frame questions, identify missing information, prepare aggregate summaries, or coordinate an agreed response. The role should not be described as the sole owner unless the formal structure says so. Causality assessment, expedited reporting, signal management, reference safety information, investigator communication, ethics submissions, and protocol changes may involve designated safety staff, responsible medical personnel, regulatory specialists, committees, and governance bodies.

ICH E2F defines a Development Safety Update Report as a periodic, integrated review of safety information during development.[4] Its purpose includes examining whether current information remains consistent with prior knowledge, describing new issues that could affect participant protection, and summarizing the understanding and management of risks. Preparing such an assessment requires more than counting events. It asks whether patterns change the benefit-risk view or the safeguards in current trials.

If you have to write an escalation note, it states:

1. What is known and from which cutoff.
2. What remains uncertain or missing.
3. How the observed event compares with disease background and prior information.
4. Which ongoing participants or studies could be affected.
5. Which immediate and longer-term options exist.
6. Who has decision authority and by when.
7. What documentation and communication each option requires.

Speed and accuracy both matter. Overstating an incomplete pattern can disrupt a program and confuse investigators. Delaying a credible safety concern can put participants at risk. Defined thresholds, coverage, and governance keep the answer from depending on one person's intuition, including yours.

Prepare benefit-risk discussions that remain decision-specific#

Benefit-risk is not a single score attached to a product for all time. It depends on population, indication, disease severity, treatment alternatives, dose, duration, uncertainty, and values. The same evidence can support one use and not another.

Medical management may organize benefit-risk dimensions, identify the most decision-relevant outcomes, and test whether positive and negative evidence use comparable denominators and follow-up. A frequent error is comparing a common short-term benefit with a rare harm that needs longer observation without acknowledging the time mismatch.

Absolute effects are often more informative than relative effects. A relative reduction can translate into a small absolute benefit when baseline risk is low. Rare serious harm may matter even when average efficacy is favorable. Missing data and excluded populations belong in the assessment, not only a list of observed outcomes.

Governance material should also state the alternative. The relevant comparison may be no treatment, another therapy, deferred treatment, or a different monitoring plan. A favorable result against placebo does not automatically establish value against current care.

Coordinate multi-regional development without assuming regions are interchangeable#

ICH E17 addresses multi-regional clinical trials conducted under one protocol across more than one region.[3] It recommends early consideration of intrinsic and extrinsic factors that could influence treatment effects and interpretation.

Intrinsic factors can include genetic and physiological characteristics. Extrinsic factors can include medical practice, diet, environment, healthcare access, diagnostic patterns, and use of concomitant therapies. The point is not to stereotype regions. It is to identify plausible sources of variation early enough to design for them.

Medical coordination may help answer:

• Is the disease defined and staged consistently across regions?
• Does the comparator represent accepted care everywhere?
• Are doses and background therapies used similarly?
• Do outcome instruments translate conceptually as well as linguistically?
• Can sites perform the procedures to the same quality standard?
• Are important subpopulations represented in sufficient numbers?
• Could regional event rates alter feasibility or interpretation?
• Which findings need planned regional or subgroup assessment?

Regional consistency does not mean every point estimate must be identical. Small regional samples produce unstable estimates. Interpretation considers direction, magnitude, uncertainty, biological plausibility, and differences in conduct. Medical, statistical, and regulatory reasoning need to meet rather than operate in separate documents.

Turn cross-functional debate into an inspectable decision#

Global development brings legitimate tension. Operations may favor a simpler visit schedule. Safety may request more monitoring. Statistics may warn that a change affects power or multiplicity. Regulatory colleagues may identify different regional expectations. Sites may report feasibility problems. Patient input may reveal a burden the internal team underestimated.

The medical function can help create a decision packet that makes these dependencies visible. A strong packet includes the question, evidence, assumptions, options, benefits, risks, operational effects, regulatory implications, and recommendation. It names the decision owner and records dissent or residual uncertainty, so that a year later you can still see why the call was made.

Meeting attendance is not the outcome. A meeting succeeds when the decision is clear, its reasoning is traceable, actions have owners and dates, and downstream documents become consistent. The article on regulatory meetings across drug development describes one external interface; the same preparation discipline applies internally.

Keep role boundaries explicit#

A medical manager does not become the treating clinician for participants by virtue of sponsor employment. Investigators remain responsible for participant care and trial conduct at their sites under applicable requirements. Sponsor medical personnel can answer protocol-related questions, but local clinical judgment and emergency care cannot be outsourced to a distant development role.

The role also does not replace:

• A regulator, which makes public regulatory decisions under law.
• An ethics committee, which provides independent ethical review.
• An independent data monitoring committee, when one is established.
• A statistician, who owns specialized statistical work.
• A pharmacovigilance or safety function with assigned legal duties.
• Quality assurance, which provides a separate assurance perspective.
• Commercial or promotional functions, whose objectives and controls differ.

Separation protects both science and accountability. Conflicts should be disclosed and managed, and access to unblinded interim data must be restricted to people with a defined need because inappropriate access can change conduct and compromise trial integrity.[2]

What good performance looks like#

Useful indicators focus on the evidence and decisions produced:

• Protocol questions are clinically coherent and feasible.
• Medical queries receive timely, consistent, documented answers.
• Emerging safety information reaches the right governance pathway.
• Study documents agree on population, endpoints, risks, and rationale.
• Decisions identify assumptions, uncertainty, alternatives, owners, and follow-up.
• Regional differences are planned for rather than discovered at submission.
• Data collection remains proportionate to participant protection and reliable results.
• Interpretations do not outrun the design or evidence.

Metrics such as review turnaround time can support operations, but speed alone can reward shallow review. The quality test is whether decisions are more reliable, understandable, and traceable because medical expertise was applied.

For more context, see clinical-trial protocol design, clinical study reports, and clinical-trial phases. The site's research overview connects clinical development methods with evidence appraisal.

The durable definition#

Describe a medical manager by the clinical decisions and interfaces you can point to on paper, not by prestige attached to the title. The function is valuable when it connects disease knowledge, emerging evidence, participant protection, regional context, and governance while leaving formal accountability exactly where the documented system places it.

References#

1. ICH E6(R3): Good Clinical Practice, Principles and Annex 1
2. ICH E8(R1): General Considerations for Clinical Studies
3. ICH E17: General Principles for Planning and Design of Multi-Regional Clinical Trials
4. ICH E2F: Development Safety Update Report